Massachusetts Governor Deval L. Patrick Pays Visit to WuXi PharmaTech (NYSE: WX)
Feb 14, 2007
December 14, 2007 - Shanghai, China - WuXi PharmaTech (NYSE: WX), China's premier provider of pharmaceutical R&D outsourcing services announced today that Governor Deval L. Patrick of the Commonwealth of Massachusetts, accompanied by other members of Massachusetts China Partnership Official Delegation, paid a visit to the company on December 7 in Shanghai, China.
Massachusetts China Partnership Official Delegation visitors included representatives from Massachusetts life science industry and academia such as Joshua Schafer Boger, Chief Executive Officer of Vertex Pharmaceuticals, and Jack Martin Wilson, President of University of Massachusetts.
Massachusetts is the U.S.'s epicenter for biotechnology, with over 300 biopharmaceutical companies located in the state. With the intellectual resources of leading universities and healthcare institutions, biotechnology has become one of the most important industries in Massachusetts.
During the meeting between the honorable guests and the management team of the company, Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech, gave Governor Patrick a brief introduction of the company and hoped for more collaboration opportunities between the two parties for continued expansion of the biopharmaceutical industry.
"I am here to encourage the collaboration that WuXi PharmaTech has with Massachusetts companies such as Vertex, and with enterprises everywhere that have the interest and ability to contribute to the future of healing," commented Governor Patrick in his address. "This collaboration has benefits for both Massachusetts and China, and for the future of health care all over the world. Working together, we will be stronger and more successful than we ever could be working apart."
The Governor added, "As in the United States, China's population is aging and life science is helping to alleviate suffering and improve quality of life for so many. By helping to find new treatments and cures while lowering health care system cost, life science gives us the opportunity to do well while doing good."
Commenting on the delegation's visit, Joshua Boger, Vertex Pharmaceuticals CEO and official delegation member said, "Through our over four years of cooperation, WuXi PharmaTech has become a trusted and important partner for our business. A trip to WuXi PharmaTech is a must-do for any life sciences company visiting China."
As China's leading provider of pharmaceutical R&D outsourcing services, WuXi PharmaTech helps more than 20 Massachusetts pharmaceutical and biotech companies accelerate their drug discovery from idea to market.
"We are much honored to host Governor Patrick and his delegation. WuXi PharmaTech has cultivated deep relationships with the financial and life science industries in Massachusetts. With the trust from our customers and support from the government, we look forward to serving more pharma and biotech companies in Massachusetts," commented Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech.
About WuXi PharmaTech (Cayman) Inc.
WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec. For more information, please visit: www.wuxiapptec.com.